AI Article Synopsis
- Malignant pleural mesothelioma (MPM) is a serious cancer mainly linked to asbestos exposure, and this study investigates noninvasive biomarkers for its diagnosis.
- A total of 30 MPM patients and 25 control subjects were analyzed, with biomarker levels measured through an enzyme immunoassay and statistical tests applied to evaluate the results.
- The study found that several biomarkers (neopterin, periostin, YKL-40, Tenascin-C, and IDO) were significantly higher in MPM patients compared to controls, suggesting they could be useful for early diagnosis of MPM.
Article Abstract
Introduction: Malignant pleural mesothelioma (MPM) is a malignant tumor that is associated mostly with asbestos exposure. The present study was to evaluates the diagnostic value of neopterin, periostin, YKL-40, Tenascin-C (TNC), and Indolamine 2,3-dioxygenase (IDO) as noninvasive markers of malign pleural mesothelioma.
Methods: Included in the study were 30 patients diagnosed with malign pleural mesothelioma, and 25 people as a control group. Biomarker levels were determined using an enzyme immunoassay . A Mann-Whitney U test and Spearman correlation methods were used for the statistical analysis.
Results: All evaluated biomarkers were found to be significantly higher in the MPM group than in the control group ( < 0.05). There was no effect of such variables as gender, age or MPMsubtype on the parameters ( > 0.05) in the patient group. All biomarkers were positively correlated with each other ( < 0.001).
Conclusions: The current non-invasive biomarkers that can be used in the diagnosis of MPM yielded significant results and can make important contributions to the early diagnosis of MPM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/09603271211017324 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!